Metagenomi Q2 net loss widens cash runway seen through 2027

Metagenomi Therapeutics

10/08/2026 21:21

Overview
Genome editing firm's Q2 net loss widened to $27.5 mln, loss per share was $0.73
Company ended Q2 with $120.7 mln in cash, expects runway through Q4 2027
Metagenomi on track to submit IND for MGX-001 hemophilia A program in Q4 2026

Outlook
Metagenomi expects to complete IND-enabling studies for MGX-001 by end-Q3 2026
Company remains on track to submit IND application for MGX-001 in Q4 2026
Company anticipates cash runway to support operations through Q4 2027

Result Drivers
PIPELINE ADVANCEMENT - Co said it continued to advance MGX-001 hemophilia A program toward IND submission, with IND-enabling studies expected to complete by end of Q3 2026
RECOGNITION OF PRECLINICAL DATA - Co highlighted two scientific posters on MGX-001 received awards at 2026 ISTH Congress, including one with extensive non-human primate data

Company press release: ID:nGNX96vMKY

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
 
$0.73
 
Q2 Net Loss
 
$27.48 mln
 
Q2 Income from Operations
 
-$28.77 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Metagenomi Therapeutics Inc is $9.00, about 631.7% above its August 7 closing price of $1.23

Reuters Recommended Reads
Aug 10 - Cogent Biosciences Q2 net loss widens on higher expenses
Aug 10 - Sionna scraps genetic disorder drug program after trial setback; shares tank
Aug 10 - Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)